|
시장보고서
상품코드
1991458
시롤리무스 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Sirolimus Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
시롤리무스 시장 규모는 2025년 2억 9,444만 달러에서 2026년부터 2034년까지 CAGR 3.99%로 확대되어 2034년에는 4억 1,871만 달러에 달할 것으로 예상됩니다.
세계 시롤리무스 시장은 장기 이식 후 거부반응 예방 및 특정 질환의 치료에 중요한 역할을 하면서 꾸준히 성장하고 있습니다. 시롤리무스는 신장 및 기타 장기 이식 환자에게 일반적으로 사용되는 면역억제제입니다. 이 약은 면역체계를 억제하여 신체가 이식된 장기를 거부하는 것을 방지합니다. 이식 수술 건수의 증가가 이 약의 수요 확대에 크게 기여하고 있습니다.
이식 의료의 발전과 장기 이식 후 환자의 생존율 향상 등 몇 가지 요인이 시장 성장을 견인하고 있습니다. 병원과 이식센터는 장기적인 치료 결과를 보장하기 위해 시롤리무스와 같은 효과적인 면역억제요법에 의존하고 있습니다. 또한, 이 약물은 특정 암 및 혈관 질환에 대한 새로운 치료 용도로도 연구되고 있어 잠재적 적용 범위가 더욱 확대되고 있습니다.
의학 연구 분야에서 시롤리무스의 새로운 치료 용도가 계속 모색되고 있기 때문에 시롤리무스 시장의 향후 전망은 여전히 유망합니다. 제제 기술의 발전으로 약물전달 효율과 환자의 치료 순응도를 향상시킬 수 있습니다. 신흥국의 의료 인프라 확충과 이식 수술 건수 증가도 시장 성장을 뒷받침할 것으로 예상됩니다. 장기 이식이 보편화됨에 따라 시롤리무스와 같은 면역억제요법에 대한 수요는 증가할 것입니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 시롤리무스 시장 : 용도별
제5장 세계의 시롤리무스 시장 : 투여 경로별
제6장 세계의 시롤리무스 시장 : 투여량별
제7장 세계의 시롤리무스 시장 : 유통 채널별
제8장 세계의 시롤리무스 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSM 26.04.14The Sirolimus Market size is expected to reach USD 418.71 Million in 2034 from USD 294.44 Million (2025) growing at a CAGR of 3.99% during 2026-2034.
The global sirolimus market has grown steadily due to its important role in preventing organ transplant rejection and treating certain medical conditions. Sirolimus is an immunosuppressive drug commonly used in patients who have undergone kidney or other organ transplants. It works by suppressing the immune system to prevent the body from rejecting the transplanted organ. The increasing number of transplant procedures has significantly contributed to the demand for this medication.
Several factors are driving market growth, including advancements in transplant medicine and improved patient survival rates after organ transplantation. Hospitals and transplant centers rely on effective immunosuppressive therapies such as sirolimus to ensure successful long-term outcomes. The drug is also being explored for additional therapeutic uses in certain cancers and vascular conditions, further expanding its potential applications.
The future outlook for the sirolimus market remains promising as medical research continues to explore new therapeutic uses for the drug. Advances in pharmaceutical formulations may improve drug delivery and patient adherence to treatment. Expanding healthcare infrastructure and increasing transplant procedures in emerging economies are also expected to support market growth. As organ transplantation becomes more common, the demand for immunosuppressive therapies like sirolimus is likely to increase.
MARKET SEGMENTATION
By Application
- Organ Transplant Rejection
- Lymphangioleiomyomatosis (LAM)
- Sirolimus Coated Balloons and Catheter Devices
By Route of Administration
- Injection
- Tablets
By Dosage
- 0.5mg
- 1mg
- 2mg
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
COMPANIES PROFILED
- Accord Healthcare Limited, Apotex Inc, Amneal Pharmaceuticals Inc, Actiza Pharmaceutical Private Limited, Biocon Limited, Concept Medical Ltd, Concord Biotech Limited, Dr Reddys Laboratories Ltd, Intas Pharmaceuticals Ltd, Livzon Pharmaceutical Group Inc, Pfizer Inc, Tiefenbacher API Ingredients GmbH Co KG, Torrent Pharmaceuticals Ltd, Zydus Group
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL SIROLIMUS MARKET: BY APPLICATION 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Application
- 4.2. Organ Transplant Rejection Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Lymphangioleiomyomatosis (LAM) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Sirolimus Coated Balloons and Catheter Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL SIROLIMUS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Route Of Administration
- 5.2. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL SIROLIMUS MARKET: BY DOSAGE 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Dosage
- 6.2. 0.5mg Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. 1mg Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. 2mg Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL SIROLIMUS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast Distribution Channel
- 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL SIROLIMUS MARKET: BY REGION 2022-2034 (USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Application
- 8.2.2 By Route Of Administration
- 8.2.3 By Dosage
- 8.2.4 By Distribution Channel
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Application
- 8.3.2 By Route Of Administration
- 8.3.3 By Dosage
- 8.3.4 By Distribution Channel
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Application
- 8.4.2 By Route Of Administration
- 8.4.3 By Dosage
- 8.4.4 By Distribution Channel
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Application
- 8.5.2 By Route Of Administration
- 8.5.3 By Dosage
- 8.5.4 By Distribution Channel
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Application
- 8.6.2 By Route Of Administration
- 8.6.3 By Dosage
- 8.6.4 By Distribution Channel
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL SIROLIMUS INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 Accord Healthcare Limited
- 10.2.2 Apotex Inc
- 10.2.3 Amneal Pharmaceuticals Inc
- 10.2.4 Actiza Pharmaceutical Private Limited
- 10.2.5 Biocon Limited
- 10.2.6 Concept Medical Ltd
- 10.2.7 Concord Biotech Limited
- 10.2.8 Dr. Reddy's Laboratories Ltd
- 10.2.9 Intas Pharmaceuticals Ltd
- 10.2.10 Livzon Pharmaceutical Group Inc
- 10.2.11 Pfizer Inc
- 10.2.12 Tiefenbacher API + Ingredients GmbH & Co. KG
- 10.2.13 Torrent Pharmaceuticals Ltd
- 10.2.14 Zydus Group
